Administration

行政

• 批准号: 10158410
• 负责人: Ruth Margrit Ruprecht
• 金额: $ 13.41万
• 依托单位: UNIVERSITY OF LOUISIANA AT LAFAYETTE
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10158410
• 关键词: Achievement; Acquired Immunodeficiency Syndrome; Address; Area; Biomedical Research; Biotechnology; Budgets; Businesses; Cold Chains; Collaborations; Communication; Country; Europe; European; Goals; HIV vaccine; HIV-1; Image; Immunology; Individual; Infectious Agent; Institutes; Institution; Intellectual Property; Lead; Louisiana; Macaca mulatta; Manuscripts; Medicine; Modeling; Monitor; Mucous Membrane; National Institute of Allergy and Infectious Disease; Needles; Oral; Positron-Emission Tomography; Primates; Protocols documentation; Publications; Radionuclide Imaging; Reagent; Reporting; Research; Research Institute; Research Personnel; Resources; Sampling; Science; Scientist; Ships; Site Visit; Solid; Switzerland; Technology; Texas; Time; Training; Travel; United States National Institutes of Health; Universities; Vaccines; Viral Pathogenesis; Virginia; Virosomes; Visit; Washington; base; capsule; data dissemination; design; dosage; experimental study; ileum; immunogenicity; innovation; manufacturing process; material transfer agreement; meetings; nonhuman primate; novel vaccines; payment; prevent; programs; simian human immunodeficiency virus; skills; vaccine delivery; vaccine development; whole body imaging

The overall objective of administrative Core A is to provide this multi-PI, multi-institutional U19 IPCAVD Project the opportunity to interact synergistically by facilitating the communication among the Project Leaders and all participating scientists. Core A will also serve as liaison between Research Administration at the contact institution, the Texas Biomedical Research Institute (TxBiomed), all the affiliated institutions both in the US and in Europe, and NIAD representatives. The network of partnering scientists includes researchers in Texas, Louisiana, Georgia and several countries in Europe; the major partner is Mymetics in Switzerland. The innovative biotech company has developed gp41-based virosomes into to a novel vaccine platform that is cold-chain independent and can be administered mucosally without needles. The Specific Aims of Core A are to: 1. Provide administrative support and facilitate the collaboration among Projects 1 and 2 and the various subcontract/subaward leaders and partners. This will include the exchange of information, reagents, and material transfer agreements. 2. Set priorities, monitor progress and jointly make go/no-go decisions. This will be achieved with input from the External Scientific Advisory Board (ESAB) and the NIAID IPCAVD Program Officer. 3. Assist in the design of experiments in rhesus macaques (RMs), protocol design and submission, and exchange of samples between the New Iberia Research Center (NIRC), where the primate studies will be conducted, and TxBiomed. 4. Provide statistical support for all IPCAVD scientists through the participation of Dr. Sarah Ratcliffe through a subaward with the University of Virginia (UVA). 5. Provide financial oversight and assure prompt payment of bills as well as the timely achievement of the experimental goals within budget limits. 6. Organize the yearly NIH Site Visit and the External Scientific Advisory Board (ESAB) meeting in the Washington, D.C. area, as well as individual visits between Drs. Ruprecht, Villinger, Santangelo and Fleury. 7. Address intellectual property (IP) issues fairly, timely, and equitably. 8. Facilitate the submission of reports, dissemination of data at meetings, and publication of manuscripts. To meet the goals of this translational, highly interactive U19 Research Program, the Core A Leader/Contact PI depends on the trained professionals with excellent organization skills as well as basic understanding of science and medicine to make this U19 network of scientists successful.

行政核心 A 的总体目标是提供这个多 PI、多机构 U19 IPCAVD 项目 通过促进项目负责人和所有人员之间的沟通，提供协同互动的机会 参与的科学家。核心 A 还将担任研究管理部门之间的联络人 机构、德克萨斯生物医学研究所 (TxBiomed)、美国和美国的所有附属机构 欧洲和 NIAD 代表。合作科学家网络包括德克萨斯州的研究人员， 路易斯安那州、乔治亚州和欧洲几个国家；主要合作伙伴是瑞士的Mymetics。创新的 生物技术公司已将基于 gp41 的病毒颗粒开发成一种新型冷链疫苗平台 独立且无需针头即可通过粘膜给药。 核心 A 的具体目标是： 1. 提供行政支持并促进项目 1 和 2 以及各个项目之间的协作 分包/分包领导者和合作伙伴。这将包括信息、试剂和 材料转让协议。 2. 设定优先事项、监控进展情况并共同做出继续/不继续的决定。这将通过输入来实现 来自外部科学顾问委员会 (ESAB) 和 NIAID IPCAVD 项目官员。 3. 协助恒河猴（RM）实验设计、方案设计和提交、 新伊比利亚研究中心 (NIRC) 之间交换样本，灵长类动物研究将在该中心进行 进行，和 TxBiomed。 4.通过Sarah Ratcliffe博士的参与为所有IPCVD科学家提供统计支持 通过弗吉尼亚大学 (UVA) 的子奖项。 5. 提供财务监督，确保及时支付账单以及按时实现目标 预算范围内的实验目标。 6. 组织年度 NIH 实地考察和外部科学顾问委员会 (ESAB) 会议 华盛顿特区，以及博士之间的个人访问。鲁普雷希特、维林格、桑坦杰洛和 弗勒里。 7. 公平、及时、公正地解决知识产权问题。 8. 促进报告的提交、会议数据的传播和稿件的出版。 为了实现这一转化性、高度互动的 U19 研究计划的目标，核心 A 负责人/联系人 PI 取决于训练有素的专业人员，具有出色的组织能力以及对科学的基本了解 和医学使这个 U19 科学家网络取得成功。